Dr Gary Blick at IAS 2023. Photo by Roger Pebody/AidsmapA history of virologic failure on antiretroviral treatment does not affect the response when people who are virally suppressed switch to a two-drug regimen of dolutegravir and lamivudine (Dovato), even if they have resistance to lamivudine, results of the SOLAR-3D study show.
Presenting SOLAR-3D last month at the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Dr Gary Blick said the findings had the potential to reduce drug costs and drug exposure for people who are not currently eligible for treatment with a two-drug regimen of dolutegravir and lamivudine.
A two-drug regimen of dolutegravir and lamivudine (Dovato) is currently recommended as a switch option for treatment-experienced people with HIV who are virologically suppressed, but only if they have no history of treatment failure and no prior or current resistance to either dolutegravir or lamivudine.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
Long-acting injectable HIV treatment highly effective in people with a detectable viral load and adherence challenges
-
Gilead provides update on clinical studies evaluating GS-1720 and/or GS-4182 for the treatment of HIV-1 infection
-
Abacavir-based ART regimens linked to higher MACE risk in patients with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.